PARTICIPATION OF BIOMARKERS FABP4, ENDOCAN, PAI-1 TO THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN PREDIABETES CONDITION
Introduction. The search of tools for the early detection of conditions associated with both carbohydrate metabolism disorders and the early development of endothelial dysfunction (ED), which subsequently leads to the development of cardiovascular events, continues currently. There are a large number of it for assessing these conditions, we settled on the most sensitive, reliable, economically low-cost methods: studying the biomarkers of endothelial dysfunction Endocan, FABP4, PAI-1 and ultrasound determination of intima media thickness in patients with prediabetes, risk of T2DM.
Aim. the participation and contribution of biomarkers: FABP4, Endocan, PAI-1 to study on the development of ED in patients with prediabetes.
Search strategy. This review primarily includes data from original studies, literature reviews found in Scopus, Web of Science, and Pubmed (Medline) databases, using appropriate keywords. The depth of the search was twenty years, due to the limited number of studies conducted on this topic and the relatively recent and growing interest of researchers in this field.
Results. All three biomarkers (FABP4, Endocan, PAI-1) appear in the early stages of endothelial dysfunction, when the development of cardiovascular events is reversible, which is the interest for the further research. Moreover, these biomarkers are responsible for different pathogenetic mechanisms of the development of endothelial dysfunction, and their combination allows one to immediately evaluate lipid metabolism disorders (FABP4), endothelial damage (Endocan), and increased thrombus formation (PAI-1). Thus, it is more accurate to establish the appearance of endothelial dysfunction in the early stages of carbohydrate metabolism disorder and prediabetes. It is worth noting that studies assessing the level of endothelial dysfunction biomarkers in patients with prediabetes and the risk T2DM have been poorly studied. And also their simultaneous association in conjunction with the study of intima media thickness in patients with prediabetes and the risk of T2DM has not been carried out at all.
Conclusions. It is scientific interest to study these markers of endothelial dysfunction at the prenosological stage, in the absence of vascular accidents manifested by diabetic micro - and macroangiopathies. Studying this issue will identify successful tools for future early detection and prevention of vascular injury and CVE.
Viktoriya F. Parakhina1, https://orcid.org/0000-0003-4250-6125
Yelena M. Laryushina1, http://orcid.org/0000-0002-9590-690X
Olga A. Ponomareva1, http://orcid.org/0000-0002-0222-5794
1 NСJSC «Medical University of Karaganda», Karaganda, Republic of Kazakhstan.
1. Атлас диабета. IDF (International Diabetes Federation). Седьмое издание, Брюссель, Бельгия. 2015 год. С. 90-94
2. Всемирная организация здравоохранения. Информационный бюллетень. Диабет. Ноябрь 2016. http://www.who.int/mediacentre/factsheets/fs312/ru/ (Дата обращения: 1.12.2023)
3. Всемирная Организация Здравоохранения. Профили сахарного диабета в странах, 2016. Женева, Швейцария, 2016. http://who.int/diabetes/country-profiles/kaz_ru.pdf (Дата обращения: 1.12.2023)
4. Здоровье населения Республики Казахстан и деятельность организаций здравоохранения в 2015 году: Стат. сборн. - Астана, 2016. 358 с. http://www.mzsr.gov.kz/sites/default/files/sbornik_za_2015_dlya_razmeshcheniya_na_sayte.pdf (Дата обращения: 1.12.2023)
5. Иванов В.В., Шахристова Е.В., Степовая Е.А., Носарева О.Л. Окислительный стресс: Влияние на секрецию инсулина, рецепцию гормона адипоцитами и липолиз в жировой ткани // Бюллетень сибирской медицины, 2014, Т.13, №3, С. 32–39.
6. Калашникова М.Ф., Буденная И.Ю., Учамприна В.А. Предиабет: современные критерии диагностики и перспективы лечения // Вестник Репродуктивного Здоровья, Март, 2009. 2-5. С. 6-13.
7. Мельникова Ю.С., Макарова Т.П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней // Казанский медицинский журнал. 2015, Т. 96. №4, С. 659-660.
8. Перцева Н.О. Состояние эндотелиальной функции у больных сахарным диабетом 2 типа с артериальной гипертонией в условиях хорошей компенсации гипергликемии // Российский медико-биологический вестник имени академика И.П. Павлова, 2014. №4, С.88-91.
9. Таратухин Е.О. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям EASD / ESC // Российский кардиологический журнал 2014. №3, С.19-20
10. Adly A.A., Elbarbary N.S., Ismail E.A., Hassan S.R. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness // J Diabetes Complications. 2014. May-Jun. 28(3):340-7.
11. Balta S., Mikhailidis D.P., Demirkol S., Ozturk C. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study // Angiology. 2014 Oct., 65(9):773-7.
12. Bao Y., Lu Z., Zhou M., Li H., Wang Y. et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women // PLoS One. 2010. 6(4): e19115.
13. Bastelica D., Morange P., Berthet B., Bordhi H., Lacroix O., Grino M., Juhan-Vague I., Alessi M.C. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits // Arteriosclerosis, Thrombosis, and Vascular Biology, 2002. Vol. 22, no. 1, pp.173–178/
14. Boord J.B., Maeda K., Makowski L., Babaev V.R. Adipocyte fatty acid binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia // Arterioscler Thromb Vas Biol. 2002. 22: 1686–1691.
15. Brown A.E., Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome // Curr Cardiol Rep. 2016 Aug. 18(8):75. doi: 10.1007/s11886-016-0755-4. PMID: 27312935; PMCID: PMC4911377.
16. Cabre A., Babio N., Lázaro I. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study // Atherosclerosis. 2012 May. 222(1):229-34
17. Cabre A., Lazaro I., Cofan M., Jarauta E. FABP4 plasma levels are increased in familial combined hyperlipidemia // J Lipid Res. 2009. 51(5):1173–8.
18. Cabre A., Lazaro I., Girona J., Manzanares J.M. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients // Atherosclerosis. 2007. 195:e150–8.
19. Cabre A., Lazaro I., Girona J., Manzanares J.M. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria // Clin Chem. 2008. 54: 181–7.
20. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimo´n F. et al. Plasma fatty acid-binding protein 4 is associated with atherogenic dyslipidemia in diabetes // J Lipid Res. 2008. 49: 1746–51.
21. Cardiovascular deseases. WHO. Key facts. June 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (Дата обращения: 1.12.2023)
22. Cesana F., Giannattasio C., Nava S., Soriano F., Brambilla G., Baroni M., et al. Impact of blood glucose variability on carotid artery intima media thickness and distensibility in type 1 diabetes mellitus // Blood Press. 2013. 22:355–61.
23. Chen Y.-Q., Su M., Raja Walia R., Hao Q., Cowington J.W., Vaughan D.E. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells // J Biol Chem. 2002. 273: 8225–8231.
24. Cikrikcioglu M.A., Erturk Z., Kilic E. Endocan and albuminuria in type 2 diabetes mellitus // Ren Fail. 2016, Nov. 38(10):1647-1653.
25. Clemente-Postigo M., Queipo-Ortun˜o M.I., Fernandez-Garcia D. Adipose tissue gene expression of factors related to lipid processing in obesity // PLoS One 6(9): (2011) e24783.
26. Coll B., Cabre A., Alonso-Villaverde C., Lazaro I., Aragone´s G. et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients // Atherosclerosis. 2008. 199: 147–53.
27. Dallio M., Masarone M., Caprio G.G. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study // J Gastrointestin Liver Dis. 2017 Sep. 26(3).
28. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria // Arch Intern Med. 2001 Feb 12. 161(3):397-405.
29. Del Turco S., Gaggini M., Daniele G., Basta G., Folli F., Sicari R., Gastaldelli A. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk // Curr Pharm Des. 2013. 19(13):2420-31.
30. Drolet R., Richard C., Sniderman A.D., Mailloux J., Fortier M. et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women // Int J Obes (Lond). 2008. 32(2): 283–291.
31. Einarson T.R., Hunchuck J., Hemels M. Relationship between blood glucose and carotid intima media thickness: a meta-analysis // Cardiovasc Diabetol. 2010. 9:37.
32. Erzen B., Sabovic M. In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction // Heart Vessels. 2013. 28: 570–577.
33. Festa A., D'Agostino R.Jr., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study // Diabetes. 2002 Apr. 51(4):1131-7.
34. Festa A., Williams K., Tracy R.P., Wagenknecht L.E., Haffner S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes // Circulation. 2006 Apr 11. 113(14):1753-9.
35. Fisher R.M., Eriksson P., Hoffstedt J., Hotamisligil G.S., Thorne A. et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals // Diabetologia. 2001. 44(10): 1268–1273.
36. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets/ // Nat Rev Drug Discov 7: 2008 489–503.
37. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association // Circulation, march, 2019. V. 139(10), p.56-528.
38. Hertzel A.V., Bernlohr D.A. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function // Trends Endocrinol Metab. 2000. 11: 175–180.
39. Hill M.A., Yang Y., Zhang L., Sun Z., Jia G., Parrish A.R., Sowers J.R. Insulin resistance, cardiovascular stiffening and cardiovascular disease // Metabolism. 2021 Jun. 119:154766.
40. International Diabetes Federation. IDF Diabetes Atlas, 8th edition. Brussels, Belgium: International Diabetes Federation, 2017. Available from: http://www.diabetesatlas.org; last accessed on 23 January, 2019 (Дата обращения: 1.12.2023)
41. Incalza M.A., D'Oria R., Natalicchio A., Perrini S., Laviola L., Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases // Vascul Pharmacol. 2018 Jan. 100:1-19.
42. Iana S. Intima-media thickness: appropriate evaluation and proper measurement // the e-Journal of Cardiology Practice. Vol. 13, N° 21 - 05 May 2015.
43. Janus A., Szahidewicz-Krupska E., Mazur G., Doroszko A. Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders // Hindawi Publishing Corporation Mediators of Inflammation Volume 2016, Article ID 3634948, 10 p.
44. Joseph F. Polak, Quenna Wong, W. Craig Johnson, David A. Bluemke, Anita Harrington, Daniel H. O'Leary, N. David Yanez. Associations of cardiovascular risk factors, carotid intima-media thickness and left ventricular mass with inter-adventitial diameters of the common carotid artery: the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis. 2011 October. 218(2): 344–349.
45. Jung R.G., Motazedian P., Ramirez F.D., Simard T., Santo P.D., Visintini S., Faraz M.A., Labinaz A., Jung Y., Hibbert B. et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis // Thrombosis Journal. 2018. 16:12.
46. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H. et al. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients // Diabetes Care. 2009. 32: 147–15.
47. Kundi H., Gok M., Kiziltunc E., Topcuoglu C. The Relationship Between Serum Endocan Levels With the Presence of Slow Coronary Flow: A Cross-Sectional Study // Clin Appl Thromb Hemost. 2017 Jul. 23(5):472-477.
48. Kundi H., Balun A., Cicekcioglu H. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction // Angiology. 2017 Jan. 68(1):46-51.
49. Lalic K., Nedeljkovic M., Jotic A., Babic R., Rajkovic N., Popovic L., Lukic L., Milicic T., Lukac S.S., Stosic L., Macesic M., Rasulic I., Gajovic J.S., Lalic N.M. Endothelial dysfunction of coronary arteries in subjects without diabetes: an association with both insulin resistance and impaired insulin secretion response // Diabetes Res Clin Pract. 2018 May.139:179-187.
50. Laryushina Y., Parakhina V., Turgunova L., Sheryazdanova D., Dosmagambetova R., Turmukhambetova A., Ponamareva O., Orbetzova M. Association of Plasminogen Activator Inhibitor-1 and Cardiovascular Events Development in Patients with Prediabetes // Macedonian Journal of Medical Sciences. 2021 Aug.81 28. 9(B):726-33. Available from: https://oamjms.eu/index.php/mjms/article/view/6825 (Дата обращения: 1.12.2023)
51. Laryushina Y., Parakhina V., Turmukhambetova A., Turgunova L., Ibraeva L., Amirkhanova D., Nildibayeva F. The Relationship Between the Level Fabp4, Risks of Type 2 Diabetes Mellitus, and Cardiovascular Events // Macedonian Journal of Medical Sciences. 2020 Oct 10; 8(B):762-768. https://doi.org/10.3889/oamjms.2020.4678. eISSN: 1857-9655 (Дата обращения: 1.12.2023)
52. Liu M., Ao L., Hu X., Ma J., Bao K., Gu Y. et al. Infuence of blood glucose fuc tuation, C-peptide level and conventional risk factors on carotid artery intima-media thickness in Chinese Han patients with type 2 diabetes mellitus // Eur J Med Res. 2019. 24:13.
53. Lv Y., Zhang Y., Shi W. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients With Type 2 Diabetes Mellitus // Am J Med Sci. 2017 May. 353(5):433-438.
54. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M. Adipocyte/ macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes // Cell Metab. 2005. 1: 107–119.
55. Makowski L., Boord J.B., Maeda K., Babaev V.R. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis // Nat Med. 2001. 7: 699–705.
56. Maria G., Isaac S., David А., Rafel R., Xavier B., Ruth M., Eric de G., Roman J.A., Jaume M., Nino K., Roberto E. Carotid intima-media thickness in the Spanish population: reference ranges and association with cardiovascular risk factors // Rev Esp Cardiol (Engl Ed). 2012 Dec. 65(12):1086-93.doi: 10.1016/j.recesp.2012.04.026. Epub 2012 Sep 28.
57. Makowski L., Hotamisligil G.S. Fatty acid binding-proteins-the evolutionary crossroads of inflammatory and metabolic responses // J Nutr. 2004. 134: 2464S–2468S.
58. Moore K.J., Shah R. Introduction to the Obesity, Metabolic Syndrome, and CVD Compendium // Circ Res. 2020 May 22. 126(11):1475-1476.
59. Muniyappa R., Sowers J.R. Role of insulin resistance in endothelial dysfunction // Rev Endocr Metab Disord. 2013. Mar.14(1):5-12.
60. Novo S., Peritore A., Trovato R.L., Guarneri F.P., Di Lisi D., Muratori I. et al. Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up // Cardiovasc Diabetol. 2013. 12:155.
61. Odegaard A.O., Jacobs D.R., Sanchez O.A., Goff D.C., Reiner A.P., Gross M.D. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes // Cardiovasc Diabetol. 2016, Mar 24.15:51.
62. Pandolfi A., Cetrullo D., Polishuck R., Alberta M.M., Calafiore A., Pellegrini G., Vitacolonna E., Capani F., Consoli A. Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects // Arteriosclerosis, Thrombosis, and Vascular Biology. 2001, 1 August. Volume 21, Issue 8, p.1378-1382.
63. Parakhina V., Laryushina Y., Ponamareva O. Association between Endocan, PAI-1 and intima media thickness in patients with high diabetes risk // Bulletin of the Karaganda University; Byology, Medicine, Geography. 2022. № 2(106) pp143-144.
64. Prieto D., Contreras C., Sánchez A. Endothelial dysfunction, obesity and insulin resistance // Curr Vasc Pharmacol. 2014 May. 12(3):412-26.
65. Qiu C.R., Fu Q., Sui J., Zhang Q. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance // Angiology. 2017 Apr; 68(4):354-359.
66. Qiu Q.Y., Zhang B.L., Zhang M.Z. Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of Inner Mongolians in China // Biomed Environ Sci. 2018. Apr. 31(4):300-305.
67. Ryden L. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD // Grant European Heart Journal. 2013. 34, 3035–3087.
68. Scherpereel A., Gentina T., Grigoriu B. Overexpression of endocan induces tumor formation // Cancer Res. 2003 Sep 15. 63(18):6084-9.
69. Somodi S., Seres I., Lőrincz H., Harangi M., Fülöp P., Paragh G. Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects // Int J Endocrinol. 2018 May 30. 2018:9596054.
70. Stejskal D., Karpisek M. Adypocite fatty acid binding protein in Caucasian population: a new marker of metabolic syndrome? // Eur J Clin Invest 2006. 36: 621–625.
71. Sun D., Man W., Zhang L. Roles of Insulin Resistance, Endothelial Dysfunction and Lifestyle Changes in the Development of Cardiovascular Disease in Diabetic Patients // Curr Drug Targets. 2017. 18(15):1792-1799.
72. The National Register of the Republic of Kazakhstan; 2021. Available from: http://www.rcrz.kz/files/sbornik/sbornik_2020-converted.pdf (Дата обращения: 1.12.2023)
73. Tso A., Xu A.W., Sham P., Wat N.M., Wang Y. et al. Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes // Diabetes Care, 2007. 30: 2667–2672.
74. Tretjakovs P., Jurka A., Bormane I., Mikelsone I., et al. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina // Clinica Chimica Acta. 2012; 413: 25–29
75. Wilson P.W., D’Agostino R.B., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus // Circulation. 2005. 112:3066–3072.
76. World Health Organization, Health of the Population of the Republic of Kazakhstan and the Activities of Health Organizations in 2017/Stat, p. 354, World Health Organization, Astana, Kazakhstan, 2018.
77. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. http://apps.who.int/iris/bitstream/10665/94384/5/9789244506233_rus.pdf?ua=1 (Дата обращения: 1.12.2023)
78. Wilkins E., Wilson L., Wickramasinghe K., Bhatnagar P., Leal J., Luengo-Fernandez R., Burns R., Rayner M., Townsend N. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels. file:///C:/Users/User/OneDrive/%D0%A0%D0%B0%D0%B1%D0%BE%D1%87%D0%B8%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB/European%20cardiovascular%20disease%20statistics%202017.pdf (Дата обращения: 1.12.2023)
79. Xu A., Tso A.W., Cheung B.M., Wang Y. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study // Circulation, 2007. 115: 1537–1543.
80. Xu A., Wang Y., Yu S.J., Stejskal D., Tam S. Adypocite fatty acidbinding protein is a plasma biomarker associated with obesity and Metabolic Syndrome // Clin Chem. 2006. 52: 405–413.
81. Yeung D.C.Y., Xu A., Cheung C.W.S. Serum Adipocyte Fatty Acid-Binding Protein Levels Were Independently Associated With Carotid Atherosclerosis // Arterioscler Thromb Vasc Biol. 2007. 27:1796-1802.
82. Yilmaz M.I., Romano M., Basarali M.K., Elzagallaai A., Karaman M., Demir Z., Demir M.F., Akcay F., Seyrek M., Haksever N., Piskin D., Cimaz R., Rieder M.J., Demirkaya E. The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study // Sci Rep. 2020 Jun 2. 10(1):9018.
83. Yuan-Yuan Z., Hong-Mei Q., Ying Y., Yuan-Yuan H. Analysis of risk factors for carotid intima-media thickness in patients with type 2 diabetes mellitus in Western China assessed by logistic regression combined with a decision tree model // Diabetol Metab Syndr. 2020. Jan 28.12:8.
References: [1-9]
1. Atlas diabeta IDF (International Diabetes Federation) Sed'moe izdanie [IDF DIABETES ATLAS Seventh Edition]. Brussels, Belgium. 2015, pp 90-94.
2. Vsemirnaya organizatsiya zdravookhraneniya. Informatsionnyi byulleten' [World Health Organization. News bulletin. Diabetes]. November 2016. http://www.who.int/mediacentre/factsheets/fs312/ru/ (accessed: 1.12.2023) [in Russian]
3. Vsemirnaya Organizatsiya Zdravookhraneniya. Profili sakharnogo diabeta v stranakh [World Health Organization. Country profiles of diabetes mellitus], http://who.int/diabetes/country-profiles/kaz_ru.pdf, 2016. Geneva, Switzerland, 2016. (accessed: 1.12.2023) [in Russian]
4. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsii zdravookhraneniya v 2015 godu: Stat. sborn. [Health of the population of the Republic of Kazakhstan and the activities of healthcare organizations in 2015: Stat. collection]. Astana, 2016. 358 p. http://www.mzsr.gov.kz/sites/default/files/sbornik_za_2015_dlya_razmeshcheniya_na_sayte.pdf. (accessed: 1.12.2023) [in Russian]
5. Ivanov V.V., Shahristova E.V., Stepovaya E.A., Nosareva O.L. Okislitel'nyi stress: Vliyanie na sekretsiyu insulina, retseptsiyu gormona adipotsitami i lipoliz v zhirovoi tkani [Oxidative stress: Effect on insulin secretion, hormone reception by adipocytes and lipolysis in adipose tissue]. Byulleten' sibirskoi meditsiny [Bulletin of Siberian Medicine]. 2014, V.13, №3, pp. 32–39. [in Russian]
6. Kalashnikova M.F., Budennaya I.Yu., Uchamprina V.A.. Prediabet: sovremennye kriterii diagnostiki i perspektivy lecheniya [Prediabetes: modern diagnostic criteria and treatment prospects]. Vestnik Reproduktivnogo Zdorov'ya [Newsletter of reproduction health], 2009. Mart, 2-5. рp 6-13 [in Russian]
7. Mel'nikova Yu.S., Makarova T.P. Endotelial'naya disfunkctsya kak tsentral'noe zveno patogeneza khronicheskikh boleznei [Endothelial dysfunction as a central link in the pathogenesis of chronic diseases]. Kazanskii meditsinskii zhurnal [Kazan Medical Journal]. 2015, T.96, №4. pp. 659-660. [in Russian]
8. Pertseva N.O. Sostoyanie endotelial'noi funktsii u bol'nykh sakharnym diabetom 2 tipa s arterial'noi gipertoniei v usloviyakh khoroshei kompensatsii giperglikemii [The state of endothelial function in patients with type 2 diabetes mellitus with arterial hypertension in conditions of good compensation for hyperglycemia]. Rossiiskii mediko-biologicheskii vestnik imeni akademika I.P. Pavlova [Russian Medical and Biological Bulletin named after Academician I.P. Pavlova]. 2014, №4, pp.88-91. [in Russian]
9. Taratuhin E.O. Rekomendatsii po diabetu, prediabetu i serdechno-sosudistym zabolevaniyam EASD/ESC [Recommendations for diabetes, prediabetes and cardiovascular diseases EASD/ESC]. Rossiiskii kardiologicheskii zhurnal [Russian Journal of Cardiology]. 2014, №3, pp.19-20. [in Russian]
Количество просмотров: 723
Категория статей:
Обзор литературы
Библиографическая ссылка
Parakhina V.F., Laryushina Ye.M., Ponomareva O.A. Participation of biomarkers FABP4, Endocan, PAI-1 to the development of endothelial dysfunction in prediabetes condition // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 6, pp. 181-190. doi 10.34689/SH.2023.25.6.021Похожие публикации:
UNDERSTANDING OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN AT THE PRESENT STAGE. REVIEW.
ГЕМОДИНАМИЧЕСКИ ЗНАЧИМЫЙ ОТКРЫТЫЙ АРТЕРИАЛЬНЫЙ ПРОТОК У НЕДОНОШЕННЫХ НОВОРОЖДЕННЫХ ДЕТЕЙ. ОБЗОР ЛИТЕРАТУРЫ
RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
ПРЕРЫВИСТАЯ КАТЕТЕРИЗАЦИЯ МОЧЕВОГО ПУЗЫРЯ КАК «ЗОЛОТОЙ СТАНДАРТ» ЛЕЧЕНИЯ НЕЙРОГЕННОГО МОЧЕВОГО ПУЗЫРЯ У ЛИЦ, С ПОВРЕЖДЕНИЕМ СПИННОГО МОЗГА
АНАЛИЗ ОПЫТА МЕДСЕСТЕР И ФАКТОРОВ, ВЛИЯЮЩИХ НА ДОБРОВОЛЬНОЕ СООБЩЕНИЕ ОБ ИНЦИДЕНТАХ